U.S. Markets open in 24 mins.

Amarin Corporation plc (AMRN)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
4.16-0.03 (-0.72%)
At close: 4:00PM EDT
People also watch
  • all the makings for a run into the 5 range on a second leg up here. Options are prices high which means the market sees a possible spike
  • If this doesn't make it above the last point of resistance, look out below...
  • Nice volume!!
  • Here comes 5 months of slowly trickling down.
  • Is there anyone else here playing with options based on a possible surprise of 80% interim DMC? I would like to discuss your strategy
  • out at 4.10 gsta.
  • Second leg gone!
  • From Sam81 at iHub
    Q2-2017 vs. Q2-2016 (Retail ONLY Data)
    TRx: 287,124 {vs 200,804; +42.99%} – Sector -0.94% --- ATH
    NRx: 113,911 {vs 80,275; +41.90%} – Sector +0.58% --- ATH
    Ref: 173,213 {vs 120,529; +43.71%} – Sector -1.85% --- ATH
    Gen L
    TRx: 698,830 {vs 780,280; -10.44%}
    NRx: 261,672 {vs 288,100; -9.17%}
    TRx: 18,262 {vs 32,666; -44.09%}
    NRx: 6,158 {vs 11,159; -44.82%}
    V Q2-2017 Retail ONLY TRx Market Share: 28.59% vs 19.81% in Q2-2016 -- ATH
    V Q2-2017 Retail ONLY NRx Market Share: 29.84% vs 21.15% in Q2-2016 -- ATH
    V Q2-2017 Retail ONLY Ref Market Share: 27.83% vs 19.00% in Q2-2016 -- ATH
  • Why is this dropping down any updates
    ACRX (MC $98 M) ( Cash $72 M)FDA Decision on October 12 for potential Blockbuster & P3 Readout this month for another Drug = 500%++ POTENTIAL !!! Undiscovered Stock please do your own dd and realize the MEGA Potential ! Thank You

    AcelRx Pharma (ACRX)

    Market Cap $97.5 Million
    Cash: $72 Million
    Price $2.15

    Upcoming Major Milestones

    Zalviso Phase 3 Results in July 2017
    DSUVIA PDUFA Date October 12, 2017
    Zalviso NDA Resubmission in Q4 2017
    DSUVIA CHMP Opinion in 1H 2018 (EU Approval)
    Zalviso FDA approval expected in Q2 2018

    Biotech Catalyst Play: AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) ...

    There is one major catalyst set to hit press at some point during July and a subsequent catalyst slated for mid-October. If both come out as positive for the company, there is considerable upside potential on the cards. We are talking the potential to go from a $3 million revenues quarterly company to one targeting markets with a combined $1.5 billion in sales with just two drugs.

    There is what we are watching out for.
    So, the first catalyst, the July catalyst, derives from an ongoing phase 3 study of a drug called Zalviso.

    So that is the first catalyst; for the second one we have to move to the start of the final quarter, specifically, October.

    In parallel to Zalviso, AcelRx is also trying to get a drug called DSUVIA approved in the US. This one is also a pain drug, this time designed for the treatment of moderate-to-severe pain in a medically supervised setting. The company submitted an NDA for the asset at the end of last year and, in February this year, the FDA accepted the submission for consideration. On acceptance, the agency set a PDUFA day of October 12, 2017, meaning it will make a decision as to whether it is willing to approve the drug before or on that date.

    While Zalviso is our near-term catalyst, the DSUVIA decision probably holds more weight from a valuation perspective. Why? Because peak sales for this one are estimated at a little over $1.1 billion in the US alone. If FDA gives a green light for commercialization to the asset, therefore, the company could have a blockbuster drug on its hands. Combine that with the close to $400 million in revenues potential from Zalviso, and AcelRx could very justifiably become a multibillion-dollar biotech company before the end of the decade.

    Biotech Catalyst Play: AcelRx Pharmaceuticals Inc (NASDAQ:ACRX)
    We have had some big winners over the last month or so with our Biotech Catalyst series and here is another one to take a look at. The company is AcelRx Pharmaceuticals Inc (NASDAQ:ACRX), a junior biotechnology stock-based out of California with a ma
  • anyone know when we expect to see any data? is Sept the date or something before?
  • Some months back I created a reminder to sell half my AMRN shares today.
    I can't remember the reason.
  • Volume matched at halftime.
  • Average volume reached a milestone today at 4.6million! Looking good before Reduce-it trial comes out! Go big or go home!
  • Lot's of insider selling recently. What's up with that.
  • Matched the average volume in just over a half hour. Go Long's!
  • What's with the high volume lately and very little price movement? It's getting locked down at this price. What signals are you guys getting from this price action? TIA
  • nice SP movement and volume...particularly volume on a short trading day in the market. Have a fantastic 4th of July...and thank you to all our vets for allowing us our independence.
  • When is the next read-out on the Reduce-it trial?
  • Look at the three month chart. Someone knows something!